Although follow-up data for this cohort are lacking, limiting causal inference, a randomized controlled trial of Saroglitazar, a dual PPAR–a/g agonist aimed at reducing hepatic fat in steatotic liver disease, demonstrated that LS detected a global improvement in NMR lipoprotein profile alongside triglyceride reduction, supporting the possible causal link to the observed lipoprotein abnormalities [18]. Here, PPARA is linked to liver disorder.